Skip to search formSkip to main contentSkip to account menu

INNO-406

Known as: Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-, CNS-9 
National Institutes of Health

Related topics

Related topics

2 relations
NS-187

Broader (1)

bafetinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Abstract LB-305: The tyrosine kinase inhibitor bafetinib (INNO-406) inhibits osteoclast formation and bone resorption
Lyn phosphorylation up-regulates several kinases including Syk, phospholipase Cγ2 and phosphatidyl inostitol-3 kinase through the… 
Review
2010
Review
2010
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells
Resistance to the BCR-ABL tyrosine kinase inhibitor imatinib poses a pressing challenge in treating chronic myeloid leukemia (CML… 
2010
2010
Synergistic Anti-Myeloma Effects of the Lyn Kinase Inhibitor INNO-406 In Combination with Doxorubicin, Melphalan and Bortezomib
Abstract 5015 Lyn is a member of the Src kinase (SFK) family and controls the activation threshold of multiple signaling pathways… 
Review
2008
Review
2008
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
The development of imatinib has changed the management of chronic myeloid leukemia (CML), producing high response rates in most… 
Highly Cited
2007
Highly Cited
2007
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia
Bcr-Abl is the cause of Philadelphia-positive (Ph+) leukemias and also constitutes their principal therapeutic target, as… 
Review
2007
Review
2007
NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
Protein kinases catalyze the transfer of the γ-phosphoryl group of adenosine triphosphate (ATP) to the hydroxyl groups of protein… 
2007
2007
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO‐406 in newly established K562 variants with BCR‐ABL gene amplification
Because imatinib (IM) resistance in chronic myeloid leukemia is primarily caused by the re‐establishment of Abl kinase, new… 
Review
2007
Review
2007
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality… 
2007
2007
[Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for…
Imatinib mesylate (Gleevec) has dramatically changed the strategy of chronic myeloid leukemia (CML) therapy. However, resistance… 
Review
2006
Review
2006
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-positive leukemia such as chronic myeloid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)